Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 39 for:    GDC-0973 | Recruiting, Not yet recruiting, Available Studies

Cobimetinib for BRAF-wild-type Histiocytoses (COBRAH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04007848
Recruitment Status : Recruiting
First Posted : July 3, 2019
Last Update Posted : August 2, 2019
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

COBRAH is a randomized double-blind 2-steps controlled superiority trial, with 2 parallel groups.

Patients will be randomly assigned in a 2:1 ratio to receive Cobimetinib orally or placebo during the first 12-weeks step, allowing the determination of the primary criteria.


Condition or disease Intervention/treatment Phase
Disease or R Group Histiocytoses Drug: Cobimetinib Drug: Placebo oral tablet Phase 3

Detailed Description:

Histiocytoses are rare multisystemic disorders characterized by accumulation of histiocytes in various organs. Virtually all the patients have a somatic mutation in the RAS-RAF-MEK-ERK pathway. BRAF inhibitors are efficacious to treat BRAF-mutated patients but one third of the patients are BRAF-wild type. For these patients, preliminary data have shown an efficacy of the MEK inhibitor cobimetinib. This trial aims to evaluate the efficacy of cobimetinib for treating BRAF-wild type patients with L or R group histiocytoses.

The primary objective of the COBRAH trial is to demonstrate that the rate of objective metabolic response (complete or partial) according to PERCIST criteria is higher under Cobimetinib versus placebo.

The objective metabolic response according to PERCIST criteria (Haroche, et al. 2015) is defined by the Positron Emission Tomography (PET) response and will be used to evaluate the overall therapeutic response at month 3 (Week 12).

For PERCIST criteria, a quantitative analysis of uptake will be performed using the standard uptake value (SUV). Fitting regions of interest covering pathologic uptake will be used to define target lesions. PERCIST will be used to classify the patients as complete metabolic response, partial metabolic response (reduction of a minimum of 30% in target lesions), stable metabolic disease or progressive metabolic disease.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cobimetinib for BRAF-wild-type Histiocytoses : a Randomized, Placebo-controlled, Double Blind Study" COBRAH Study
Actual Study Start Date : July 25, 2019
Estimated Primary Completion Date : September 22, 2021
Estimated Study Completion Date : June 22, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Cobimetinib

Arm Intervention/treatment
Experimental: Cobimetinib
Experimental group : 36 histiocytoses's patients without BRAF V600E will be randomised in cobimetinib group
Drug: Cobimetinib
Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets
Other Name: COTELLIC

Placebo Comparator: Placebo
Control group : 18 histiocytoses's patients without BRAF V600E will be randomised in the placebo group
Drug: Placebo oral tablet
Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
Other Name: PLACEBO




Primary Outcome Measures :
  1. The objective metabolic responses [ Time Frame: at month 3 ]

    The objective metabolic responses is the percentage of patients with a complete metabolic response, partial metabolic response (reduction of a minimum of 30% in target lesions), stable metabolic disease or progressive metabolic disease according to PERCIST criteria (Haroche, et al. 2015) at Month 3. PERCIST criteria is defined by the PET response and will be used to evaluate the overall therapeutic response at month 3.

    For PERCIST criteria, a quantitative analysis of uptake will be performed using the standard uptake value (SUV). Fitting regions of interest covering pathologic uptake will be used to define target lesions. PERCIST will be used to classify patients metabolic response.



Secondary Outcome Measures :
  1. Overall survival [ Time Frame: every 12 weeks up to 36 weeks for Cobimetinib group and 48 weeks for Placebo group ]
    Overall survival is defined as the time between the date of randomisation and the death.

  2. Progression-free survival [ Time Frame: every 12 weeks up to 36 weeks for Cobimetinib group and 48 weeks for Placebo group ]
    Progression-free survival is defined as the time between the date of randomisation and the first documented event of disease progression according to PERCIST criteria (Haroche, et al. 2015).

  3. Number of participants with adverse events as assessed by CTCAE v4.0 [ Time Frame: From the randomisation up to 36 weeks for Cobimetinib group and 48 weeks for Placebo group. ]
    All adverse events from clinical evaluations and laboratory measurements assessed by CTCAE v4.0

  4. Overall response of Cobimetinib (metabolic and tumor assessment) [ Time Frame: From the evaluation performed just before the treatment (Day 0 for Cobimetinib group, Week 12 for Placebo group) ]
    Overall response of Cobimetinib (metabolic and tumor assessment) assessed after 36 weeks of Cobimetinib treatment or until Cobimetinib stop.

  5. CRP levels [ Time Frame: At Baseline, Week 12, Week 24, Week 36 and Week 48 (for Placebo group) ]
    CRP levels assessed from blood samples



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligible patients should be at least 18 years of age,
  • Have a histologically confirmed L or R group histiocytoses without BRAFV600E mutation detected with the use of a real-time polymerase chain reaction,
  • Have a measurable disease according to the PERCIST criteria with presence of at least one severe organ involvement (heart, vascular, central nervous system) OR a multisystemic disease with ≥3 organ involvement AND failure of a first-line treatment or contra-indication to these treatments,
  • Accepting effective contraception during treatment duration (men and women childbearing potential) and 3 months after.
  • Signed informed consent

Exclusion Criteria:

  • Patients with severe hepatic, renal and cardiac outcomes
  • Patients with myopathies at baseline
  • Patients with retinal detachment at baseline
  • Patients with inherited disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  • Patients with high bleeding risk.
  • Allergies to iodized contrast media
  • Simultaneous participation in another medical research
  • Pregnancy or breast-feeding.
  • No affiliation to the French Health Care System "sécurité sociale"

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04007848


Contacts
Layout table for location contacts
Contact: Fleur Dr COHEN AUBART +33142178242 fleur.cohen@aphp.fr
Contact: Julien Pr HAROCHE +33142178037 julien.haroche@aphp.fr

Locations
Layout table for location information
France
Service de Médecine interne - La Pitié Salpêtrière Recruiting
Paris, France, 75013
Contact: Fleur Dr COHEN AUBART    +33142178242    fleur.cohen@aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Fleur Dr COHEN AUBART APHP

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04007848     History of Changes
Other Study ID Numbers: P170932J - 2018-00222-23
First Posted: July 3, 2019    Key Record Dates
Last Update Posted: August 2, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Histiocytosis
Lymphatic Diseases